EP Patent

EP2687213B1 — Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof

Assigned to Amgen Europe GmbH · Expires 2019-01-23 · 7y expired

What this patent protects

Patent listed against Otezla.

Drugs covered by this patent

Patent Metadata

Patent number
EP2687213B1
Jurisdiction
EP
Classification
—
Expires
2019-01-23
Drug substance claim
No
Drug product claim
No
Assignee
Amgen Europe GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.